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Abstract
Currently there is a great deal of interest in developing methods for testing the role that rare variation plays in
disease development. Here we propose a weighted association test that accumulates genetic variation across a
signaling pathway. We evaluate our approach by analyzing simulated phenotype data from an exome sequencing
study of 697 unrelated individuals from the Genetic Analysis Workshop 17 (GAW17) data set. Although our
weighted approach identifies several interesting pathways associated with phenotype Q1, so does an alternative
unweighted accumulation approach. Such a result is not unexpected because there is no systematic relationship
between the allele frequency of a variant and its effect on phenotype in the GAW17 simulation model.
Background
Next-generation sequencing technology allows for the
characterization of virtually all of an individual’s genetic
variation. Genome-wide association studies (GWAS) have
successfully detected hundreds of disease-susceptible loci
that harbor common variants. However, the common
variants identified so far have explained only a small por-
tion of the genetic risk of most of the diseases studied.
Some researchers have argued that this is due in part to
rare variants having a larger role in disease etiology than
previously suspected. Some recent studies support this
reasoning [1-11].
Several approaches have been proposed to analyze rare
variants for association with disease. The cohort allelic
sums test (CAST) is a simple grouping method that com-
pares the number of affected and unaffected individuals
who have variants [4,12,13]. Li and Leal [14] introduced
the combined multivariate and collapsing (CMC)
method. In CMC, markers in a gene or other unit of ana-
lysis are collapsed into one or more indicator variables
based on some criteria (e.g., the presence of at least one
nonsynonymous mutation within a gene). Because many
criteria could be used to define several such indicator
variables, Li and Leal proposed a multivariate test using
Hotelling’s T. Morris and Zeggini [15] proposed an accu-
mulation approach that regresses phenotype on a genetic
score, defined as the proportion of sites within the gene
or pathway that harbor mutations. Price et al. [16] pro-
posed a variable-threshold approach by finding the maxi-
mum z-score across all possible values for threshold T,
assuming that the variants having minor allele frequency
under this threshold are more likely to be functional.
Madsen and Browning [12] proposed a weighted sum
statistic. In this approach, single-nucleotide polymorph-
isms (SNPs), which are rare among the control subjects,
are up-weighted with the goal of giving rare, highly pene-
trant mutations greater influence on the test statistic.
Here, we propose a weighted group-wise association test
that accumulates genetic variation across a signaling path-
way. We extend the basic idea behind the Madsen and
Browning [12] weighting scheme to quantitative traits.
Specifically, genetic markers that are rare among indivi-
duals in the center of the phenotypic distribution (those
with nonextreme phenotypes) are up-weighted to reflect
the assumption that rare genetic variation will tend to
have a larger effect on a phenotype. Because the weight is
af u n c t i o no fp h e n o t y p e ,a si nM a d s e na n dB r o w n i n g ’s
study [12], permutation is used to assess statistical signifi-
cance. In the next section, we detail our approach and
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any medium, provided the original work is properly cited.highlight its application to phenotype Q1 of the Genetic
Analysis Workshop 17 (GAW17) data.
Methods
Suppose that the number of SNPs in a genetic unit (a
signaling pathway or a gene) is P.L e tYi, i =1 ,2 ,…, N,
be the phenotype for individual i.W ed e f i n eIij for indi-
vidual i to be the number of minor alleles at SNP j.L e t
Xi be a genetic summary score, which we define as:
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where wj is a weight that is applied to the jth SNP.
We evaluate two weighting schemes. In the first
scheme, wj is taken to be 1 for all j. Thus rare and com-
mon SNPs are treated in the same way, and Xi is the
simple sum of the number of minor alleles in the gene
or pathway. This approach is similar to that of Morris
and Zeggini’s method [15]; they defined a genetic score
by the proportion of sites within the gene or pathway
that harbored mutations. Because this scheme does not
differentially weight SNPs, we refer to it as unweighted.
In the second scheme, we calculate the frequency of
nonreference mutations among nonextreme individuals
at position j as:
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where δ(Yi)=1w h e nYi is within one standard devia-
tion of the mean and δ(Yi) = 0 otherwise. Adding a 1 to
the numerator and a 2 to the denominator ensures that
the frequency pj is nonzero, so that the weight used in
the second scheme,
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remains finite [12]. Note that, with this weight, SNPs
that are rare among those individuals whose phenotypes
lie within the center of the phenotype distribution will
be up-weighted and will have a larger role in the genetic
summary score Xi. We refer to this scheme simply as
weighted.
For both approaches, once we have defined the
genetic score Xi, we assume that it is related to Yi
through the linear model:
YX ii  bb e 01 ++ , (4)
where ε is an unknown error term. A Wald statistic,
ˆ /[ (ˆ )]
/ bb 11
12 Var , is computed, with the variance
estimated using a sandwich estimator [17]. Because the
weighted approach uses phenotypic information in
defining the weight, we use permutation to assess statis-
tical significance. We note that, in this case, the weight
is recomputed for each permuted data set. We use 1
million permutations throughout.
We evaluate our approach using the simulated GAW17
data set. These data are described in detail elsewhere [18].
Although all 200 replicates are analyzed, for illustration
purposes, we present results concerning replicate 1 in
greater detail. Our analyses focus on one phenotype: quan-
titative trait Q1. Even though we had access to the answers
for the underlying simulation model, our approach,
including the characterization of signaling pathways, was
developed without reference to these answers.
We characterize gene sets using information from two
databases. The first, PharmGKB (https://www.pharmgkb.
org/) [19], provides information on 1,400 signaling path-
ways. Unfortunately, the genes in the GAW17 data set are
not well represented in PharmGKB, with only 713 out of
3,205 genes sequenced in the GAW17 data being included
in 821 of these pathways. To compensate for this low cov-
erage, we also classify genes by biological process from the
Gene Ontology (GO) database (http://www.geneontology.
org). Although not defining a signaling pathway, the GO
biological process domain classifies genes by their involve-
ment in biological processes and therefore presents an
interesting unit over which to accumulate genetic varia-
tion. This approach allows us to classify 2,304 out of 3,205
genes into 3,009 biological processes. The GO data
are contained in two files: a human genetic association
file, dated September 15, 2010, revision 1.1433; and a
genetic ontology file, dated September 6, 2010, revision
1.160. We note that in both of these classification schemes
(PharmGKB and GO) one gene may be mapped to several
pathways or biological processes. A pathway or biological
process is taken to be significantly associated with the
phenotype if its permutation p-value does not exceed the
Bonferroni corrected significance threshold 0.05(821 +
3009) ~ 1.3055 × 10
–5. The entire analysis is repeated
using both the weighted and unweighted schemes. Only
nonsynonymous SNPs are considered throughout.
Results
The results of these analyses, applied to replicate 1, can be
found in Tables 1 and 2. Pathways (processes) with a dag-
ger are significant using the weighted approach, and path-
ways (processes) with an asterisk are significant using the
unweighted approach. Table 1 presents those PharmGKB
signaling pathways that were found to be significant by
one of the two (weighted or unweighted) approaches. It is
immediately apparent from Table 1 that trait Q1 seems to
be related to vascular endothelial growth factor (VEGF).
This, of course, is comforting, given that the simulation
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PharmGKB ID Pathway name Permutation
p-value (weighted approach)
Permutation
p-value (unweighted approach)
PA164713582†* Actions of nitric oxide in the heart 6.0 × 10
–6 <1.0 × 10
–6
PA164713652†* VEGF hypoxia and angiogenesis <1.0 × 10
–6 6.0 × 10
–6
PA164728105†* Signaling events mediated by VEGFR1 and VEGFR2 <1.0 × 10
–6 <1.0 × 10
–6
PA164728138†* S1P3 pathway <1.0 × 10
–6 <1.0 × 10
–6
PA164713890† Neurophilin interactions with VEGF and VEGFR <1.0 × 10
–6 1.7 × 10
–5
PA164714260† VEGF binds to VEGFR leading to receptor dimerization <1.0 × 10
–6 3.3 × 10
–5
PA164728144† VEGFR1-specific signals <1.0 × 10
–6 1.70 × 10
–4
PA164728199† Integrins in angiogenesis 9.0 × 10
–6 (a)
PA164728205†* S1P1 pathway 8.0 × 10
–6 1.1 × 10
–5
PA164728223† HIF-1-alpha transcription factor network <1.0 × 10
–6 1.92 × 10
–4
PA164728227†* Glypican 1 network 1.0 × 10
–6 <1.0 × 10
–6
PA2032†* VEGF pathway <1.0 × 10
–6 <1.0 × 10
–6
† Pathways (processes) that are significant using the weighted approach.
* Pathways (processes) that are significant using the unweighted approach.
Table 2 Significant GO processes
GO term Description Permutation
p-value (weighted
approach)
Permutation
p-value (unweighted
approach)
GO:0000186† Activation of MAP kinase activity, especially during sporulation <1.0 × 10
–6 4.0 × 10
–5
GO:0001569†* Branching involved in blood vessel morphogenesis <1.0 × 10
–6 <1.0 × 10
–6
GO:0001666†* Response to lowered oxygen tension <1.0 × 10
–6 1.0 × 10
–6
GO:0001938†* Up-regulation of endothelial cell proliferation <1.0 × 10
–6 <1.0 × 10
–6
GO:0002040†* Sprouting angiogenesis <1.0 × 10
–6 <1.0 × 10
–6
GO:0006355†* Regulation of cellular transcription, DNA-dependent <1.0 × 10
–6 <1.0 × 10
–6
GO:0006916* Anti-apoptosis 7.5 × 10
–5 1.0 × 10
–6
GO:0006940†* Any process that modulates the frequency, rate, or extent of smooth
muscle contraction
<1.0 × 10
–6 <1.0 × 10
–6
GO:0006952 † Defense/immunity protein activity 8.0 × 10
–6 1.9 × 10
–5
GO:0007169†* Transmembrane receptor protein tyrosine kinase signaling pathway <1.0 × 10
–6 <1.0 × 10
–6
GO:0008152† Metabolic process 3.0 × 10
–6 2.2 × 10
–5
GO:0010595†* Up-regulation of endothelial cell migration <1.0 × 10
–6 7.0 × 10
–6
GO:0030097† Blood cell formation <1.0 × 10
–6 (a)
*GO:0030522†* Intracellular receptor-mediated signaling pathway <1.0 × 10
–6 <1.0 × 10
–6
GO:0030949†* Up-regulation of vascular endothelial growth factor (VEGF) receptor
signaling pathway
<1.0 × 10
–6 <1.0 × 10
–6
GO:0043129†* Surfactant homeostasis <1.0 × 10
–6 1.1 × 10
–5
GO:0045446† Endothelial cell differentiation <1.0 × 10
–6 (a)
GO:0045745* Positive regulation of G-protein coupled receptor protein signaling
pathway
6.425 × 10
–2 1.2 × 10
–5
GO:0048286†* Lung alveolus development <1.0 × 10
–6 5.0 × 10
–6
GO:0048661†* Up-regulation of smooth muscle cell proliferation <1.0 × 10
–6 <1.0 × 10
–6
GO:0050927† Up-regulation of positive chemotaxis <1.0 × 10
–6 (a)
GO:0051894† Up-regulation of focal adhesion formation <1.0 × 10
–6 (a)
GO:0055074† Regulation of calcium ion concentration <1.0 × 10
–6 (a)
† Pathways (processes) that are significant using the weighted approach.
* Pathways (processes) that are significant using the unweighted approach.
a Once 100 permuted data sets were found to have a larger Wald statistic for a given process than that observed in the original (unpermuted) data set, that
process was deemed nonsignificant and further permutations were not performed.
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from this pathway.
Table 2 presents GO biological processes that were
found to be significant by one of the two (weighted or
unweighted) approaches. Although VEGF is clearly impli-
cated through one of the significant GO processes, the
overall importance of VEGF is far less clear. This does not
suggest that the information encoded in the GO database
is somehow inferior to that represented by PharmGKB;
it suggests only that the organization of PharmGKB makes
the involvement of VEGF more transparent in this parti-
cular analysis. Results from the analysis of the other repli-
cates are entirely similar. Almost all of the 200 replicates
clearly implicate the VEGF pathway as influencing
trait Q1. For example, using the weighted approach,
PharmGKB pathway PA2032 was found to be significant
in all 200 replicates, whereas GO process GO:0030949 was
significant in 195 of 200 replicates. The unweighted
approach performed even better, with all 200 replicates
finding both PA2032 and GO:0030949 significant.
We informally explored which genes were important in
these significant pathways and processes by enumerating
the number of times a given gene was present in a signifi-
cant pathway or process. The genes occurring in the bio-
logical processes from the GO data set are compared
with the ones in the signaling pathways from the
PharmGKB data set. Table 3 presents the top 10 genes
with the most representation in the list of significant
pathways or processes. From this table we can see that,
although the GO and PharmGKB approaches may appear
different at the pathway or process level, they seem to
identify similar structure at the gene level. The genes
VEGFA, FLT1, KDR, HIF1A,a n dARNT are consistently
represented both in the significant PharmGKB pathways
and the significant GO processes. A comparison of the
results in Table 3 with those in Table 4 suggests that the
unweighted analysis also gives similar results.
Discussion
We presented two tests (weighted and unweighted) that
accumulate genetic variation across a signaling pathway
or biological process. In the analyses presented here, we
found that the unweighted approach worked as well as,
or better than, the weighted approach. We believe that
this is strictly due to the structure of this particular simu-
lation, in which the effect sizes of causal SNPs show no
trend with the frequency of the causal variant. In situa-
tions where rarer SNPs are, in fact, more highly pene-
trant, we would expect a weighted approach to be more
powerful.
In the analyses presented here, an accumulation
approach seemed to work well. However, we must offer
two important caveats. First, when moving from a gene-
based to a pathway-based approach, the power of the
approach becomes increasingly dependent on the state
of existing biological knowledge and its representation
in databases such as PharmGKB and GO. Even though
we constructed pathways and biological processes with-
out considering the true simulation model, our results
are bound to be an overly optimistic representation of
the power of a pathway-based approach. After all, the
GAW17 simulation was constructed by accessing the
same biological knowledge (although perhaps not the
same databases) that we used to construct our pathways.
Second, we computed a genetic score by simply sum-
ming the number of mutations in a gene or pathway
and ignoring the directionality of the effect. This
approach will be powerful when mutations lead to a
shift in the phenotype in only one direction (as in the
GAW17 simulation). However, it is likely that some
mutations could lead to higher values of a phenotype
and that other mutations could lead to lower values.
This is possible even within a gene and becomes even
more likely when considering a collection of genes, such
as in a signaling pathway.
Table 3 Ten most frequent genes in significant PharmGKB pathways and GO processes using the weighted approach
PharmGKB Number of nonsynonomous SNPs GO Number of nonsynonomous SNPs
VEGFA 2 FLT1 20
FLT1 20 KDR 11
SRC 1 VEGFA 2
HSP90AA1 9 KIT 5
KDR 11 ARNT 9
PRKCA 2 PTK2B 4
HIF1A 6 HIF1A 6
PTK2 5 SHH 4
SHC1 3 ROR2 2
ARNT 9 NRP1 1
Bold denotes genes that were found using both databases.
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Table 4 Ten most frequent genes in significant PharmGKB pathways and GO processes using the unweighted
approach
PharmGKB Number of nonsynonomous SNPs GO Number of nonsynonomous SNPs
VEGFA 2 FLT1 20
FLT1 20 VEGFA 2
SRC 1 KDR 11
HSP90AA1 9 KIT 5
HIF1A 6 ARNT 9
PRKCA 2 PTK2B 4
KDR 11 PDGFB 3
SHC1 3 SHH 4
PTK2 5 EGFR 4
ARNT 9 ROR2 2
Bold denotes genes that were found using both databases.
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